Form 8-K - Current report:
SEC Accession No. 0000950170-24-125385
Filing Date
2024-11-12
Accepted
2024-11-12 16:10:09
Documents
13
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K clsd-20241112.htm   iXBRL 8-K 45491
2 EX-99.1 clsd-ex99_1.htm EX-99.1 149975
3 GRAPHIC img171462827_0.jpg GRAPHIC 29410
  Complete submission text file 0000950170-24-125385.txt   362515

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT clsd-20241112.xsd EX-101.SCH 24862
15 EXTRACTED XBRL INSTANCE DOCUMENT clsd-20241112_htm.xml XML 4719
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 241448161
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)